These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 1078720

  • 1. Therapy of intention myoclonus with L-5-hydroxytryptophan and a peripheral decarboxylase inhibitor, MK 486.
    Van Woert MH, Sethy VH.
    Neurology; 1975 Feb; 25(2):135-40. PubMed ID: 1078720
    [Abstract] [Full Text] [Related]

  • 2. Long-term therapy of myoclonus and other neurologic disorders with L-5-hydroxytryptophan and carbidopa.
    Van Woert MH, Rosenbaum D, Howieson J, Bowers MB.
    N Engl J Med; 1977 Jan 13; 296(2):70-5. PubMed ID: 401457
    [Abstract] [Full Text] [Related]

  • 3. Serotonin and myoclonus.
    Van Woert MH, Jutkowitz R, Rosenbaum D, Bowers MB.
    Monogr Neural Sci; 1976 Jan 13; 3():71-80. PubMed ID: 790170
    [Abstract] [Full Text] [Related]

  • 4. Letter: Treatment of post-anoxic intention myoclonus.
    Van Woert MH, Sethy VH.
    Lancet; 1974 Jun 22; 1(7869):1285. PubMed ID: 4134164
    [No Abstract] [Full Text] [Related]

  • 5. Post-hypoxic intention myoclonus treated with 5-hydroxy-tryptophan and an extracerebral decarboxylase inhibitor.
    Magnussen I, Dupont E, Engbaek F, de Fine Olivarius B.
    Acta Neurol Scand; 1978 Apr 22; 57(4):289-94. PubMed ID: 307327
    [Abstract] [Full Text] [Related]

  • 6. Postanoxic myoclonus. Treatment of a case with 5-hydroxytryptophane and a decarboxylase inhibitor.
    Beretta E, Regli F, de Crousaz G, Steck AJ.
    J Neurol; 1981 Apr 22; 225(1):57-62. PubMed ID: 6164757
    [Abstract] [Full Text] [Related]

  • 7. Beneficial effects of serotonin precursors in postanoxic action myoclonus.
    De Léan J, Richardson JC, Hornykiewicz O.
    Neurology; 1976 Sep 22; 26(9):863-8. PubMed ID: 1084968
    [Abstract] [Full Text] [Related]

  • 8. Clinical, biochemical, and physiological features distinguishing myoclonus responsive to 5-hydroxytryptophan, tryptophan with a monoamine oxidase inhibitor, and clonazepam.
    Chadwick D, Hallett M, Harris R, Jenner P, Reynolds EH, Marsden CD.
    Brain; 1977 Sep 22; 100(3):455-87. PubMed ID: 412560
    [Abstract] [Full Text] [Related]

  • 9. Clinical and metabolic observations on the treatment of myoclonus with L-5-HTP and carbidopa.
    Thal L, Sharpless N, Wolfson L, Engel J, Katzman R.
    Trans Am Neurol Assoc; 1976 Sep 22; 101():48-52. PubMed ID: 1088459
    [No Abstract] [Full Text] [Related]

  • 10. Manipulation of brain serotonin in the treatment of myoclonus.
    Chadwick D, Jenner P, Harris R, Reynolds EH, Marsden CD.
    Lancet; 1975 Sep 06; 2(7932):434-5. PubMed ID: 51240
    [Abstract] [Full Text] [Related]

  • 11. Fluoxetine in the treatment of intention myoclonus.
    Van Woert MH, Magnussen I, Rosenbaum D, Chung E.
    Clin Neuropharmacol; 1983 Mar 06; 6(1):49-54. PubMed ID: 6189599
    [Abstract] [Full Text] [Related]

  • 12. Biochemistry and therapeutics of posthypoxic myoclonus.
    Van Woert MH, Rosenbaum D, Chung EY.
    Adv Neurol; 1986 Mar 06; 43():171-81. PubMed ID: 2418644
    [No Abstract] [Full Text] [Related]

  • 13. Pathological findings in a case of hypoxic myoclonus treated with 5-hydroxytryptophan and a decarboxylase inhibitor.
    De Léan J, Richardson JC, Rewcastle NB.
    Adv Neurol; 1986 Mar 06; 43():215-23. PubMed ID: 2418647
    [Abstract] [Full Text] [Related]

  • 14. HVA and 5HIAA CSF measurements and 5HTP trials in some patients with involuntary movements.
    Guilleminault C, Tharp BR, Cousin D.
    J Neurol Sci; 1973 Apr 06; 18(4):435-41. PubMed ID: 4540626
    [No Abstract] [Full Text] [Related]

  • 15. Clinical, biochemical, and pharmacological observation in a patient with postasphyxic myoclonus: association to serotonin hyperactivity.
    Giménez-Roldán S, Mateo D, Muradas V, De Yebenes JG.
    Clin Neuropharmacol; 1988 Apr 06; 11(2):151-60. PubMed ID: 2454156
    [Abstract] [Full Text] [Related]

  • 16. Treatment of posthypoxic action myoclonus: implications for the pathophysiology of the disorder.
    Chadwick D, Hallett M, Jenner P, Marsden CD.
    Adv Neurol; 1986 Apr 06; 43():183-90. PubMed ID: 2418645
    [No Abstract] [Full Text] [Related]

  • 17. Treatment of myoclonus with L-5-hydroxytryptophan and carbidopa: clinical, electrophysiological, and biochemical observations.
    Thal LJ, Sharpless NS, Wolfson L, Katzman R.
    Ann Neurol; 1980 Jun 06; 7(6):570-6. PubMed ID: 6969054
    [Abstract] [Full Text] [Related]

  • 18. Palatal myoclonus treated with 5-hydroxytryptophan and a decarboxylase-inhibitor.
    Magnussen I, Dupont E, Prange-Hansen A, de Fine Olivarius B.
    Acta Neurol Scand; 1977 Mar 06; 55(3):251-53. PubMed ID: 300537
    [No Abstract] [Full Text] [Related]

  • 19. Development of a scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa.
    Sternberg EM, Van Woert MH, Young SN, Magnussen I, Baker H, Gauthier S, Osterland CK.
    N Engl J Med; 1980 Oct 02; 303(14):782-7. PubMed ID: 6997735
    [Abstract] [Full Text] [Related]

  • 20. L-5-hydroxytryptophan in treatment of several different syndromes in which myoclonus is prominent.
    Growdon JH, Young RR, Shahani BT.
    Neurology; 1976 Dec 02; 26(12):1135-40. PubMed ID: 1086988
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.